Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449736 | 1.00 | DGAT1 (0.41) | DGAT1ELANE | |
| SCHEMBL27541566 | 0.84 | DGAT1 (0.32) | DGAT1ELANE | |
| SCHEMBL27475397 | 0.79 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL28444101 | 0.77 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL27747511 | 0.72 | DGAT1 (0.50) | DGAT1ELANE | |
| SCHEMBL6687359 | 0.72 | DGAT1 (0.50) | DGAT1ELANE | |
| SCHEMBL320271 | 0.72 | DGAT1 (0.50) | DGAT1ELANE | |
| SCHEMBL6807316 | 0.71 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL5165354 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL16632764 | 0.70 | DGAT1 (0.48) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| EP-2118080-B1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2644618-B1 | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators | OCERA THERAPEUTICS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2644618-A1 | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators | Tranzyme Pharma, Inc. (CA) | 2013-10-02 | — | — | EP | disclosed |
| EP-2118080-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | Tranzyme Pharma, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008130464-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | GHSR, GHRHR, GIPR | DGAT1 864/4885ELANE 2732/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | DGAT1 1348/4885ELANE 2982/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | DGAT1 864/4885ELANE 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.